Innovating Works
HORIZON-CL6-2023-FARM2FORK-01-...
Advancing vaccine development for African swine fever
Sólo fondo perdido 0 €
Comunidad autónoma
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 12-04-2023.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

Expected Outcome:A successful proposal will support research and innovation to help policy makers and economic operators reduce the burden of African swine fever (ASF), thus contributing to a safeguarding animal health and the economic resilience of the sustainable livestock industry.

Activities under this topic will contribute to the following expected outcomes:

Improved capacity to develop ASF pilot vaccines and their companion DIVA tests for the possible prevention and/or eradication of the disease in domestic pigs and wild boars;Vaccination strategies for both wild boar and domestic pigs, addressing different objectives and needs (e.g. eradication in wild boar; emergency or preventive use in domestic pigs).Increased international cooperation on a possible ASF vaccine. Scope:ASF is a devastating viral disease that has showed its potential for very serious and rapid spread, not only in Europe, but throughout the world. It has a serious socio-economic impact on farming sector and is of major importance in the international trade of animals and animal products. While strict control measures including in particular biosecurity, culling of infected pigs, app... ver más

Expected Outcome:A successful proposal will support research and innovation to help policy makers and economic operators reduce the burden of African swine fever (ASF), thus contributing to a safeguarding animal health and the economic resilience of the sustainable livestock industry.

Activities under this topic will contribute to the following expected outcomes:

Improved capacity to develop ASF pilot vaccines and their companion DIVA tests for the possible prevention and/or eradication of the disease in domestic pigs and wild boars;Vaccination strategies for both wild boar and domestic pigs, addressing different objectives and needs (e.g. eradication in wild boar; emergency or preventive use in domestic pigs).Increased international cooperation on a possible ASF vaccine. Scope:ASF is a devastating viral disease that has showed its potential for very serious and rapid spread, not only in Europe, but throughout the world. It has a serious socio-economic impact on farming sector and is of major importance in the international trade of animals and animal products. While strict control measures including in particular biosecurity, culling of infected pigs, appropriate management of wild-boar populations, have contributed to reduced spread of the disease, concerns are raised on the possibility to eradicate the disease without vaccination in the long-term.

Global research efforts are starting to show some promising results, but further work on the development of effective and safe ASF vaccines is needed, as an additional tool to re-inforce control and eradication strategies currently in place.

All the following elements should be incorporated:

Address the necessary steps for developing pilot vaccines against ASF for domestic pigs and wild boars;Address the necessary steps to develop companion DIVA tests, where feasible.Decipher pathogen genetics/genomics and immune response of the host, to develop innovative approaches to African swine fever vaccine development, at least including those virus types circulating in Europe. Study different types of vaccines and modern techniques to develop novel ASF vaccines; In order to achieve the expected outcomes, international cooperation is encouraged in particular with North America.

The selected project should take into consideration the EU animal health regulatory framework.

Proposals should ensure adequate involvement of stakeholders from the European Medicines Agency, veterinary authorities, farmers and hunters. Involvement of the pharmaceutical industry is highly recommended.

While it is expected that proposals will present innovative approaches to ASF vaccine development, the projects could consider the relevant activities and outputs of past or ongoing EU funded research, such as VACDIVA[1] and DEFEND[2], and of other international projects on ASF vaccine and build on them where appropriate. They should contribute to the relevant objectives of the Star-Idaz International Consortium[3].

<p class="eui-u-font-s">[1] https://vacdiva.eu/

<p class="eui-u-font-s">[2] https://defend2020.eu/

<p class="eui-u-font-s">[3] https://www.star-idaz.net/

ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Comunidad autónoma :
Solo pueden aplicar a esta linea las empresas con sede en:
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:
Empresas Micro, Pequeña, Mediana, Grande
Centros Tecnológicos
Universidades
Organismos públicos

Características del Proyecto

Requisitos de diseño: Duración: ¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 4:. Es el primer paso para determinar si los componentes individuales funcionarán juntos como un sistema en un entorno de laboratorio. Es un sistema de baja fidelidad para demostrar la funcionalidad básica y se definen las predicciones de rendimiento asociadas en relación con el entorno operativo final. leer más.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Condiciones: No existe condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.